Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Boehringer's Restless Leg Syndrome Drug To Be Promoted By Neurology/Primary Care Reps

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Parkinson's agent Mirapex gains supplemental indication, will compete with GSK's Requip.

You may also be interested in...



GSK, XenoPort Will Include Two-Dose Data In NDA For Restless Legs Drug

Positive efficacy with 600 mg a "surprise," XenoPort CEO says.

GSK, XenoPort Will Include Two-Dose Data In NDA For Restless Legs Drug

Positive efficacy with 600 mg a "surprise," XenoPort CEO says.

Boehringer Inks $265 Million Alzheimer’s R&D Deal For Ablynx’s Nanobodies Technology

The contract includes options for drug development in other neurocognitive diseases, the company tells “The Pink Sheet” DAILY.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Global Pharma Guidance Tracker – March 2024

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

See All
UsernamePublicRestriction

Register

PS063350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By